Dupilumab value for atopic dermatitis backed by ICER

The Institute of Clinical and Economic Review (ICER) has issued a Final Evidence Report and summary of a public meeting of the Midwest Comparative Effectiveness Public Advisory Council (Midwest CEPAC) which concludes that Dupixent (dupilumab) from Regeneron (Nasdaq: REGN) and Sanofi (Euronext: SAN) offers good long-term value for patients with moderate-to-severe atopic dermatitis.

The report from the independent non-profit research institute, along with an accompanying Report-at-a-Glance, also assesses the comparative clinical effectiveness of Eucrisa (crisaborole) from Pfizer (NYSE: PFE) for mild-to-moderate disease.

“Our analyses showed that dupilumab offers important clinical benefit for patients with moderate-to-severe atopic dermatitis. Moreover, the drug was priced in a way that aligns well with the benefit it provides to patients,” noted David Rind, the ICER’s chief medical officer.